about
A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophenOsteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome.Mechanism of the promotion of steatotic HepG2 cell apoptosis by cholesterolMechanism of the effect of glycosyltransferase GLT8D2 on fatty liver.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Nonalcoholic fatty liver disease - current status and future directions.
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Evolving therapies for non-alcoholic steatohepatitis.
@en
type
label
Evolving therapies for non-alcoholic steatohepatitis.
@en
prefLabel
Evolving therapies for non-alcoholic steatohepatitis.
@en
P2860
P1476
Evolving therapies for non-alcoholic steatohepatitis
@en
P2093
Herbert Tilg
P2860
P304
P356
10.1517/17460441.2014.911283
P407
P577
2014-04-25T00:00:00Z